We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
201
Phathom Pharmaceuticals
PHAT
$692M
$521K 0.15%
44,306
– –
AGIO icon
202
Agios Pharmaceuticals
AGIO
$1.93B
$517K 0.15%
12,881
– –
ASND icon
203
Ascendis Pharma A/S
ASND
$16.8B
$517K 0.15%
2,600
– –
OFS icon
204
OFS Capital
OFS
$51.9M
$510K 0.15%
66,286
+4,372
+7% +$36.8K
AXSM icon
205
Axsome Therapeutics
AXSM
$10.9B
$508K 0.15%
4,183
– –
NBIX icon
206
Neurocrine Biosciences
NBIX
$16.6B
$499K 0.14%
3,555
– –
MSDL icon
207
Morgan Stanley Direct Lending Fund
MSDL
$1.3B
$487K 0.14%
30,302
+9,922
+49% +$181K
REGN icon
208
Regeneron Pharmaceuticals
REGN
$80.8B
$479K 0.14%
852
– –
SPMC
209
Sound Point Meridian Capital
SPMC
$221M
$478K 0.14%
+27,559
New +$494K
BIIB icon
210
Biogen
BIIB
$30.7B
$471K 0.13%
3,359
– –
DAWN
211
DELISTED
Day One Biopharmaceuticals
DAWN
$468K 0.13%
66,427
– –
IMCR icon
212
Immunocore
IMCR
$1.73B
$453K 0.13%
12,472
– –
WHF icon
213
WhiteHorse Finance
WHF
$146M
$451K 0.13%
65,196
+6,940
+12% +$59.4K
CELC icon
214
Celcuity
CELC
$4.52B
$448K 0.13%
9,059
+1,572
+21% +$62.9K
GILD icon
215
Gilead Sciences
GILD
$165B
$440K 0.13%
3,966
– –
EXEL icon
216
Exelixis
EXEL
$13.4B
$439K 0.13%
10,637
– –
MAIN icon
217
Main Street Capital
MAIN
$5.48B
$436K 0.12%
6,861
-1,897
-22% -$123K
ACAD icon
218
Acadia Pharmaceuticals
ACAD
$5.03B
$436K 0.12%
20,441
– –
TGTX icon
219
TG Therapeutics
TGTX
$7.62B
$430K 0.12%
11,892
– –
DVAX
220
DELISTED
Dynavax Technologies
DVAX
$424K 0.12%
42,730
– –
AMGN icon
221
Amgen
AMGN
$222B
$422K 0.12%
1,495
-4,935
-77% -$1.43M
BMRN icon
222
BioMarin Pharmaceuticals
BMRN
$12.4B
$420K 0.12%
7,758
– –
MRNA icon
223
Moderna
MRNA
$23.6B
$420K 0.12%
16,248
– –
BNTX icon
224
BioNTech
BNTX
$23.5B
$418K 0.12%
4,236
– –
IOVA icon
225
Iovance Biotherapeutics
IOVA
$2.87B
$417K 0.12%
192,378
– –
7 8
9
10 11

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.